Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2016 07:00 ET | Source: ArQule, Inc.

ArQule Reports First Quarter 2016 Financial Results

Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the first quarter of...
February 29, 2016 07:00 ET | Source: ArQule, Inc.

ArQule Reports Fourth Quarter and Full Year 2015 Financial Results

Conference Call Scheduled Today at 9:00 a.m. ET BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the fourth quarter and...
February 29, 2016 06:55 ET | Source: ArQule, Inc.

ArQule Announces $15.3 Million Registered Direct Offering of Common Stock

BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it has entered into definitive agreements with certain institutional and accredited investors to raise...
February 04, 2016 07:30 ET | Source: ArQule, Inc.

ArQule to Present at Upcoming Investor Conferences

BURLINGTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer and Dr. Brian Schwartz, Chief Medical Officer and Head of...
January 28, 2016 07:30 ET | Source: ArQule, Inc.

ArQule Provides Proprietary Pipeline Update for AKT Inhibitors

First cohort dosed in phase 1 trial with ARQ 092 in Proteus syndromeArQule receives Investigational New Drug approval for ARQ 751BURLINGTON, Mass., Jan. 28, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc....
November 04, 2015 07:00 ET | Source: ArQule, Inc.

ArQule Reports Third Quarter 2015 Financial Results

Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., Nov. 04, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the third quarter of...
October 27, 2015 07:30 ET | Source: ArQule, Inc.

ArQule to Present Data on Tivantinib, ARQ 087, ARQ 092, and ARQ 751 at AACR-NCI-EORTC Conference

Single-agent and combination pre-clinical and clinical data supportive of on-going clinical trials BURLINGTON, Mass., Oct. 27, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced...
October 15, 2015 16:00 ET | Source: ArQule, Inc.

ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 and Next Generation AKT Inhibitor ARQ 751 in Oncology

Pre-Clinical Data Supports the Use of AKT1 and PI3K Mutations as Biomarkers for the Company’s AKT Inhibitors BURLINGTON, Mass., Oct. 15, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today...
September 28, 2015 07:30 ET | Source: ArQule, Inc.

ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference

Preliminary Results of the Phase 1b Expansion Cohort Show Four Partial Responses in Targeted Patient Populations BURLINGTON, Mass., Sept. 28, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc....